Alternatives to Dovato (Dolutegravir/Lamivudine) If You Can't Fill Your Prescription

Dovato (dolutegravir/lamivudine) is a highly effective, once-daily, two-drug HIV treatment. But as a specialty medication not always in stock at every pharmacy, some patients face the unsettling situation of not being able to fill their prescription.

The most important rule: never stop your HIV medication or switch regimens on your own. Always work with your healthcare provider. That said, it helps to understand what alternatives exist so you can have an informed conversation with your doctor if Dovato truly isn't available.

Before exploring alternatives, have you tried using medfinder.com to find Dovato in stock near you? Switching regimens carries risks — try finding your prescription first.

Why Switching HIV Medications Requires Medical Supervision

HIV antiretroviral therapy is carefully matched to each patient's viral history, resistance profile, co-infections, and other medications. Switching to a different regimen without medical guidance can:

• Miss important contraindications (e.g., HLA-B*5701 status for abacavir-containing regimens)
• Fail to manage hepatitis B co-infection properly
• Create dosing gaps that allow viral rebound or resistance development
• Introduce new drug interactions with other medications you take

Always call your provider first. The alternatives below are meant to help you have an informed conversation — not to serve as a self-switching guide.

Alternative #1: Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide)

Biktarvy is the most prescribed HIV medication in the United States and is widely available at most pharmacies. Like Dovato, it is a once-daily, single-tablet complete regimen, making the transition straightforward for many patients.

Key differences from Dovato: Biktarvy contains three drugs (vs. two in Dovato) and includes tenofovir alafenamide (TAF), which also treats hepatitis B — making it the preferred option for patients co-infected with HIV and HBV. Dovato is not recommended for HBV co-infected patients; Biktarvy is.

Common side effects of Biktarvy include nausea, diarrhea, and headache. Some studies suggest Dovato may be associated with less weight gain than Biktarvy, though both are well tolerated by most patients.

Alternative #2: Triumeq (Dolutegravir/Abacavir/Lamivudine)

Triumeq contains the same integrase inhibitor backbone as Dovato — dolutegravir — but adds abacavir as a third agent alongside lamivudine. It is a once-daily, three-drug, single-tablet regimen.

Critical requirement: Patients must be tested for the HLA-B*5701 genetic marker before starting Triumeq. Those who test positive cannot take abacavir — it can cause a life-threatening hypersensitivity reaction. Like Dovato, Triumeq is not recommended for patients with HBV co-infection.

The transition from Dovato to Triumeq may be relatively smooth for appropriate patients, since both share dolutegravir and lamivudine as components.

Alternative #3: Cabenuva (Cabotegravir/Rilpivirine Injectable)

For patients who are already virologically suppressed — meaning their HIV viral load is undetectable — Cabenuva offers a completely different approach: a long-acting injectable given monthly or every two months at a clinic or doctor's office. No daily pills at all.

Cabenuva is not a direct swap for Dovato in all situations. It requires prior virologic suppression, no known resistance to cabotegravir or rilpivirine, and a commitment to regular clinic visits for injections. But for patients who are tired of the daily pill and qualify, it eliminates the pharmacy availability problem entirely.

Alternative #4: Juluca (Dolutegravir/Rilpivirine)

Juluca is another two-drug, once-daily regimen that shares dolutegravir with Dovato but pairs it with rilpivirine instead of lamivudine. It is approved for virologically suppressed adults who need to simplify or switch their regimen.

Important difference: Juluca must be taken with a meal (at least 500 calories). It is also contraindicated with proton pump inhibitors (PPIs) and certain antacids. Patients with HIV-1 RNA ≥500 copies/mL or a history of virologic failure should not use Juluca.

Comparison Summary

Here's a quick comparison of Dovato and its main alternatives:

• Dovato (DTG/3TC): 2 drugs, once daily, no food requirement, not for HBV co-infection
• Biktarvy (BIC/FTC/TAF): 3 drugs, once daily, no food requirement, treats HBV, most widely available
• Triumeq (DTG/ABC/3TC): 3 drugs, once daily, requires HLA-B*5701 test, not for HBV co-infection
• Cabenuva (CAB/RPV): 2 drugs, injectable (monthly/every 2 months), for virologically suppressed only
• Juluca (DTG/RPV): 2 drugs, once daily with food, for virologically suppressed only, no PPIs

The Bottom Line

If you can't fill your Dovato prescription, use medfinder to find a pharmacy with it in stock before considering a switch. If a switch is truly necessary, call your HIV provider immediately — they can assess which alternative is clinically appropriate for your specific situation. Never switch HIV medications without medical guidance.